Clinical Trial

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-17
minor Completion moved earlier: 2026-08 -> 2026-05-19 2026-07-17
notable Primary completion moved earlier: 2026-08 -> 2026-03-19 2026-06-27
Trial Details
NCT Number NCT06817356
Lead Sponsor Eli Lilly and Company
Conditions Alcohol Use Disorder
Enrollment 308 participants
Start Date 2025-02-06
Primary Completion 2026-03-19 (estimated)
Study Completion 2026-05-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-16